Literature DB >> 20660275

Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome.

Jose Luis Olmos-Serrano1, Scott M Paluszkiewicz, Brandon S Martin, Walter E Kaufmann, Joshua G Corbin, Molly M Huntsman.   

Abstract

Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by variable cognitive impairment and behavioral disturbances such as exaggerated fear, anxiety and gaze avoidance. Consistent with this, findings from human brain imaging studies suggest dysfunction of the amygdala. Underlying alterations in amygdala synaptic function in the Fmr1 knock-out (KO) mouse model of FXS, however, remain largely unexplored. Utilizing a combination of approaches, we uncover profound alterations in inhibitory neurotransmission in the amygdala of Fmr1 KO mice. We demonstrate a dramatic reduction in the frequency and amplitude of phasic IPSCs, tonic inhibitory currents, as well as in the number of inhibitory synapses in Fmr1 KO mice. Furthermore, we observe significant alterations in GABA availability, both intracellularly and at the synaptic cleft. Together, these findings identify abnormalities in basal and action potential-dependent inhibitory neurotransmission. Additionally, we reveal a significant neuronal hyperexcitability in principal neurons of the amygdala in Fmr1 KO mice, which is strikingly rescued by pharmacological augmentation of tonic inhibitory tone using the GABA agonist gaboxadol (THIP). Thus, our study reveals relevant inhibitory synaptic abnormalities in the amygdala in the Fmr1 KO brain and supports the notion that pharmacological approaches targeting the GABAergic system may be a viable therapeutic approach toward correcting amygdala-based symptoms in FXS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660275      PMCID: PMC2948869          DOI: 10.1523/JNEUROSCI.1714-10.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  61 in total

1.  Nucleus-specific differences in GABA(A)-receptor-mediated inhibition are enhanced during thalamic development.

Authors:  M M Huntsman; J R Huguenard
Journal:  J Neurophysiol       Date:  2000-01       Impact factor: 2.714

2.  Light and electron microscopic study of cholinergic and noradrenergic elements in the basolateral nucleus of the rat amygdala: evidence for interactions between the two systems.

Authors:  R Li; H Nishijo; Q Wang; T Uwano; R Tamura; O Ohtani; T Ono
Journal:  J Comp Neurol       Date:  2001-10-29       Impact factor: 3.215

3.  Reciprocal inhibitory connections and network synchrony in the mammalian thalamus.

Authors:  M M Huntsman; D M Porcello; G E Homanics; T M DeLorey; J R Huguenard
Journal:  Science       Date:  1999-01-22       Impact factor: 47.728

4.  Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome.

Authors:  V Brown; P Jin; S Ceman; J C Darnell; W T O'Donnell; S A Tenenbaum; X Jin; Y Feng; K D Wilkinson; J D Keene; R B Darnell; S T Warren
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

5.  The role of the synthetic enzyme GAD65 in the control of neuronal gamma-aminobutyric acid release.

Authors:  N Tian; C Petersen; S Kash; S Baekkeskov; D Copenhagen; R Nicoll
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Choline acetyltransferase activity and vesamicol binding in Rett syndrome and in rats with nucleus basalis lesions.

Authors:  G L Wenk; S L Mobley
Journal:  Neuroscience       Date:  1996-07       Impact factor: 3.590

7.  Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse.

Authors:  C E Bakker; Y de Diego Otero; C Bontekoe; P Raghoe; T Luteijn; A T Hoogeveen; B A Oostra; R Willemsen
Journal:  Exp Cell Res       Date:  2000-07-10       Impact factor: 3.905

8.  Development of a tonic form of synaptic inhibition in rat cerebellar granule cells resulting from persistent activation of GABAA receptors.

Authors:  S G Brickley; S G Cull-Candy; M Farrant
Journal:  J Physiol       Date:  1996-12-15       Impact factor: 5.182

9.  The vesicular GABA transporter, VGAT, localizes to synaptic vesicles in sets of glycinergic as well as GABAergic neurons.

Authors:  F A Chaudhry; R J Reimer; E E Bellocchio; N C Danbolt; K K Osen; R H Edwards; J Storm-Mathisen
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

Review 10.  Advances in the treatment of fragile X syndrome.

Authors:  Randi J Hagerman; Elizabeth Berry-Kravis; Walter E Kaufmann; Michele Y Ono; Nicole Tartaglia; Ave Lachiewicz; Rebecca Kronk; Carol Delahunty; David Hessl; Jeannie Visootsak; Jonathan Picker; Louise Gane; Michael Tranfaglia
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

View more
  147 in total

1.  Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.

Authors:  Laura K K Pacey; Sujeenthar Tharmalingam; David R Hampson
Journal:  J Pharmacol Exp Ther       Date:  2011-06-02       Impact factor: 4.030

Review 2.  Fragile X syndrome: the GABAergic system and circuit dysfunction.

Authors:  Scott M Paluszkiewicz; Brandon S Martin; Molly M Huntsman
Journal:  Dev Neurosci       Date:  2011-09-21       Impact factor: 2.984

3.  Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.

Authors:  S M Goebel-Goody; E D Wilson-Wallis; S Royston; S M Tagliatela; J R Naegele; P J Lombroso
Journal:  Genes Brain Behav       Date:  2012-04-06       Impact factor: 3.449

Review 4.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 5.  Moving Toward Integrative, Multidimensional Research in Modern Psychiatry: Lessons Learned From Fragile X Syndrome.

Authors:  Lawrence K Fung; Allan L Reiss
Journal:  Biol Psychiatry       Date:  2015-12-18       Impact factor: 13.382

Review 6.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

7.  Translational regulation of NeuroD1 expression by FMRP: involvement in glutamatergic neuronal differentiation of cultured rat primary neural progenitor cells.

Authors:  Se Jin Jeon; Ji-Woon Kim; Ki Chan Kim; So Min Han; Hyo Sang Go; Jung Eun Seo; Chang Soon Choi; Jong Hoon Ryu; Chan Young Shin; Mi-Ryoung Song
Journal:  Cell Mol Neurobiol       Date:  2013-12-12       Impact factor: 5.046

8.  The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.

Authors:  Jose Luis Olmos-Serrano; Joshua G Corbin; Mark P Burns
Journal:  Dev Neurosci       Date:  2011-11-08       Impact factor: 2.984

9.  Subregion-Specific Impacts of Genetic Loss of Diazepam Binding Inhibitor on Synaptic Inhibition in the Murine Hippocampus.

Authors:  Connor D Courtney; Catherine A Christian
Journal:  Neuroscience       Date:  2018-07-19       Impact factor: 3.590

10.  Emotion potentiated startle in fragile X syndrome.

Authors:  Elizabeth C Ballinger; Lisa Cordeiro; Alyssa D Chavez; Randi J Hagerman; David Hessl
Journal:  J Autism Dev Disord       Date:  2014-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.